Historic Partnership between the Weizmann Institute of Science and Institut Curie
25.3.2019 19:54:00 EET | Business Wire | Press release
On March 22, the Weizmann Institute of Science in Rehovot, Israel, and Institut Curie in Paris, France, two major world-class research institutes, signed an historic partnership that will allow their teams to work closely together to improve knowledge in the field of life sciences, particularly in the areas of physics and chemistry, and most specifically - in the field of cancer research. This is a milestone in the history of these two institutes that have been working together for 15 years, particularly in the field of biophysics.
Collaborative research programs
This partnership will extend to many disciplines, including physics,
chemistry, cellular biology, epigenetics, genetics, immunology and
single cell approaches, imagery and data collection. The complementarity
of the research between the various groups at Institut Curie and at the
Weizmann Institute has been recognized in particular at the occasion of
joint scientific workshops held regularly alternatively in Paris and
Rehovot. Each research program will be organized around a pair of
researchers with a scientist from Institut Curie and a scientist from
the Weizmann Institute of Sciences, who will receive support on the
annual basis. This partnership also includes exchanges of scientists and
a Curie-Weizmann symposium organized every two years, with alternate
locations in Rehovot, Israel, and in Paris, which will be focused on one
of the subjects of research cooperation.
To finance the start of
this cooperation, Institut Curie and the Weizmann Institute of Sciences
will finance this research program for €200,000 each, and will organize
a joint fundraiser with philanthropists and corporate sponsors.
Projects with high hopes
There are numerous common interests
between the two Institutes. They can range from the description of
defects in cell nuclei to the mechanics of cell migration, or the
behavior of neural networks. A few examples of exciting ongoing projects
are highlighted below.
During his sabbatical visit at Institut
Curie in 2012, Professor Nir Gov (Weizmann Institute) participated in
several projects ranging from cell migration to collective cell
behaviors and neuron growth. For instance, he developed a theory in
collaboration with Raphael Voituriez (Sorbonne University), which
explains the observations of the team of Matthieu Piel (Institut Curie)
on the links between persistence and speed of migrating cells. This
theory gave rise to collaborative developments between these three teams
to predict important aspects of the migratory behavior of immune cells.
He
also collaborated with Pascal Silberzan at Institut Curie to understand
the behavior of cells packed at very high density on a surface. This
joint work combining experiments and theory, has highlighted the
importance of an intrinsic biological ageing of the cell population.
This project has helped understanding how cells can come to an arrest
while maintaining a capacity to respond to external perturbations such
as an injury.
Elisha Moses (Weizmann Institute) has a longstanding
interaction with the group of Professor Jean-Louis Viovy (Institut
Curie), now headed by Stéphanie Descroix, on the applications of
microfluidic devices to the study of living neuronal networks. He spent
three months in Paris, during which he and Dr. Catherine Villard of the
Descroix lab developed an optogenetic assay for guiding axonal growth.
This work has the potential for controlling growth of neurons and of
neuronal tumors within the brain. Drs. M. Vignes and R. Renault, two
talented researchers who were working on the project as students, have
now graduated and branched off into very interesting conceptual and
practical applications of this approach.
An important complementarity
The two institutions are both
highly complementary and display many mutually common attributes.
Institut
Curie is the premier research center in France conducting cancer
research, including all facets of carcinogenesis. Its research center
brings together 1,200 researchers working in 12 joint research units
organized in four areas based on natural scientific interactions and
robust medical potentiality. A strong advocate of international
cooperation , it welcomes more than 80 nationalities. Equipped with
advanced technology platforms, it is an important resource for
researchers around the world. Institut Curie is also a state-of-the-art
hospital complex that provides care and support for all cancer types and
welcomes more than 50,000 patients each year. It has developed
particularly innovative treatments directly from the work of its
research center. Institut Curie also trains students in science and
cancer research with the goal of increasing the knowledge about the
topic.
The Weizmann Institute of Science is among the ten premier
institutes of fundamental research in the world: 2,500 scientists work
on its campus in Rehovot in the complementary fields of mathematics and
computer science, physics, biology, chemistry, and biochemistry. The
Weizmann Institute of Science has a long history of research and
discoveries rooted in a mission of advancement of science for the
benefit of humanity; cancer research accounts for 40% of the total
budget of the Institute, which shapes and hosts a large part of the
leadership in Israel and contributes to the advancement and
understanding of scientific issues among all audiences.
Both
institutions have powerful means of technology transfer that leverage
the discoveries of their labs for the benefit of patients, whether
through the creation of medications, medical devices or other
technologies.
A shared vision of science
Science at the service of people
- this is the best way to describe the credo of the two institutes, both
of which were founded upon great personalities who have made an
important mark in the history of the world.
Chaim Weizmann, chemist
and author of many discoveries and publications, is the founder of the
Weizmann Institute, and was the first president of the State of Israel
between 1949 and 1952. Marie Curie, born Maria Sklodowska, founded the
Radium Institute in 1909. The first female professor and holder of a
chair position at the Sorbonne, the first woman to win two Nobel prizes
and be enshrined at the Pantheon in Paris on her own merit. In many
ways, these two scientists have had a remarkable journey.
But
beyond these prestigious founders, the two institutes share the same
vision of science, at the service of people and driven by strong values,
the same curiosity for discovery and knowledge at the service of human
health.
The
Weizmann Institute of Science and Institut Curie also share a common
belief that international collaborations in the field of institut-curie.org
science and the exchange of ideas across interdisciplinary boundaries
can accelerate progress to the benefit of humanity.
It is this
common ground which today enables this collaboration to take root and
which will tomorrow allow us to multiply efforts and as a result enjoy
major new discoveries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190325005638/en/
Contact information
Yohan Philippe
yohan.philippe@curie.fr
+33
(0)1 56 24 55 53
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Announces Results of the Annual General Meeting2.4.2026 17:49:00 EEST | Press release
SES (the “Company”) held the Annual General Meeting (“AGM”) of Shareholders today in Betzdorf, Luxembourg. Following the recommendations made by the Board of Directors of SES, the shareholders have voted in favor of all resolutions, including the Company’s 2025 annual accounts and the proposed annual dividend of EUR 0.50 per A-share (EUR 0.20 per B-share). The total dividend amount comprises the interim dividend of EUR 0.25 per A-share (EUR 0.10 per B-share), which has already been paid to shareholders on October 16, 2025. The final dividend of EUR 0.25 per A-share (EUR 0.10 per B-share) will be paid to shareholders on April 16, 2026. “I would like to sincerely thank our shareholders for their active engagement, visionary support and continued confidence in SES’ strategy,” said Adel Al-Saleh, CEO of SES. “The outcomes of today’s AGM underscore our shared commitment to a bold multi-orbit approach, with Medium Earth Orbit as the strategic backbone of a dynamically evolving global interco
Forrester: Three Years Into GenAI, Enterprises Are Still Chasing Its True Transformative Value2.4.2026 17:00:00 EEST | Press release
According to Forrester’s (Nasdaq: FORR) latest report, Accelerate Your AI Voyage, most enterprises are struggling to turn growing AI adoption and investment into measurable business impact. One of the key factors holding businesses back is low artificial intelligence quotient (AIQ) — Forrester’s measure of AI aptitude — with many employees lacking a clear understanding of how to use AI. Other barriers include an overemphasis on productivity-focused use cases, difficulty measuring impact, and siloed adoption within individual functions. While these challenges can leave firms frozen in doubt or indecision, the wait-and-see approach to AI adoption is no longer viable. To unlock AI’s full potential, organizations need to focus on four key areas: Define the business outcomes and success metrics for what they want AI to achieve; identify specific use cases for AI deployment aligned to those business outcomes; establish a structured runway to plan, test, and strategically time the deployment
Andersen Consulting Adds Multiplica2.4.2026 16:30:00 EEST | Press release
Andersen Consulting enters into a Collaboration Agreement with Multiplica, a digital consulting firm that helps organizations design, build, and scale impactful digital experiences. Founded in Spain with a presence in Latin America and the U.S., Multiplica focuses on user research and discovery, customer experience research, digital strategy, data modeling and analysis, report automation and data visualization, conversion rate optimization, product design, and user experience design. The firm helps organizations accelerate digital transformation by building digital capabilities, teams, and assets that advance expertise across digital products, consulting, and talent development. Multiplica enables clients to forecast emerging trends in digital experience and transform their businesses through enhanced digital channels and customer engagement. “Collaborating with Andersen Consulting represents an exciting opportunity to extend our reach and impact,” said David Boronat, CEO of Multiplica
Brightfin Unifies Brand Following Proven Optics Merger, Delivering a New Standard for Technology Cost Optimization2.4.2026 16:00:00 EEST | Press release
Brightfin today announced that, following its merger with Proven Optics, the combined company will operate under a single brand: Brightfin. The unified company brings together deep expertise in Technology Expense Management (TEM) and IT Financial Management (ITFM) to help organizations better understand, manage, and reduce total technology spend. Technology spending will exceed $6 Trillion this year, and for most organizations, it remains one of the least understood. CIOs can tell you what they’re spending. Far fewer can tell you whether it’s working. “Over the past several months, we’ve brought these two businesses together around a shared purpose: help enterprise businesses better understand and optimize their technology spend,” said Joel Martins, CEO of Brightfin. “What we are seeing now is a shift. Visibility alone isn’t enough. Teams need to be able to act, tied to real financial outcomes. See Clearly. Spend Better. That is our north star, and that is what our platform is built to
The LYCRA Company Announces Strategic Partnership on Renewable LYCRA ® Fiber2.4.2026 16:00:00 EEST | Press release
The LYCRA Company, a global leader in innovative and sustainable fiber solutions for the apparel and personal care industries, today announced the signing of a strategic partnership agreement with Texhong International Group Limited (“Texhong”), one of the world’s largest suppliers of core-spun cotton textiles. Under the agreement, Texhong will exclusively partner with The LYCRA Company to bring Renewable LYCRA® fiber made with 30 percent plant-based content* to China’s core-spun yarn sector. This collaboration aims to accelerate the adoption of bio-derived spandex across the global apparel and textile industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260402505834/en/ The LYCRA Company announced a strategic partnership with Texhong International Group for renewable LYCRA® fiber. Pictured at the signing ceremony held in Shanghai (left to right): Jason Wang, Vice President, Asia, The LYCRA Company, and Zhou Xia, Chief O
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
